Bariatric Surgery is Associated with Reduction in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma: A Propensity Matched Analysis
Bariatric surgery is still not recommended to alleviate the long-term sequelae of non-alcoholic fatty liver disease (NAFLD) despite some evidence to suggest bariatric surgery can mitigate the risk of non-alcoholic steatohepatitis (NASH) and/or hepatocellular carcinoma. This current study is the first to use a propensity match analysis of a large cohort of bariatric surgery patients with non-surgery controls to show that patients who had undergone bariatric surgery had fewer new cases of NASH and HCC with extended follow up, and further risk adjustment also revealed bariatric surgery was associated with fewer cases of NASH by 48%. These results highlight the importance of bariatric surgery offering more than a procedure for sustained weight loss, but also in its potential to further abate obesity-related comorbidities, as well.
This study aims to determine the effect of type 2 diabetes mellitus and insulin therapy on non-alcoholic fatty liver disease in the patients with morbid obesity. MATERIAL AND METHODS: Clinical, anthropometric and laboratory data were analyzed together with intraoperative liver biopsies from morbidly obese patients undergoing bariatric surgery. RESULTS: 219 patients with morbid obesity were evaluated. Systemic arterial hypertension (55.9% vs. 33.8%, p = 0.004) and dyslipidemia (67.1% vs. 39.0%, p
Conclusions: While there is a certain overlap between the results of the current study and published transcriptomic profiles of non-transplanted livers with steatosis, we have identified discrete characteristics of the non-alcoholic fatty liver disease in liver grafts potentially utilizable for the establishment of predictive signature. Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in industrialized countries, its prevalence being estimated at 19–31.3% (1). It encompasses a range of conditions that are thought to arise from fatty liver (simple steatosis) throu...
Conclusions: Bariatric surgery appears to be capable of partially reversing the obesity-related epigenome. The identification of potential epigenetic biomarkers predictive for the success of bariatric surgery may open new doors to personalized therapy for severe obesity. Introduction Obesity is currently a huge healthcare problem, worldwide, and is a risk factor for several diseases such as type 2 diabetes (T2D), cardiovascular disease and cancer (1). As the prevalence of obesity reaches pandemic proportions, this metabolic disease is estimated to become the biggest cause of mortality in the near future (2). In fact,...
Authors: Martín Mateos R, Allen AM Abstract Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as the most common cause of chronic liver disease worldwide, with a global prevalence of 25.2%. The high burden of NAFLD extends beyond liver diseases, as patients are at risk of developing not only liver related conditions, including cirrhosis and hepatocellular carcinoma, but also cardiovascular complications associated to metabolic syndrome. The present special issue of The Spanish Journal of Gastroenterology (Revista Española de Enfermedades Digestivas) focusses on diverse key aspects o...
CONCLUSION: There is a close relationship between splicing machinery dysregulation and NAFLD development, which should be further investigated to identify novel therapeutic targets. PMID: 30901032 [PubMed - as supplied by publisher]
The epidemic of obesity in Western countries is accompanied by a dramatic increase in the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in both adults and adolescents . The prevalence of NAFLD is projected to increase to 33.5% among adults by 2030; consequently the incidence of hepatocellular carcinoma and liver related deaths are estimated to increase by 137% and 178% respectively, in the same time frame .
ConclusionsNAFLD could be dealt with laparoscopic sleeve gastrectomy, preventing its progression into cirrhosis. SG can be performed in patients with obesity and metabolic syndrome, with NAFLD showing satisfactory results 12 months after surgery. NAFLD should be a formal indication for bariatric surgery.
Authors: Wong VW Abstract Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease worldwide and the second leading indication for liver transplantation and the third leading cause of hepatocellular carcinoma (HCC) in the United States. This chapter focuses on the prevention and management of NAFLD. Healthy lifestyle is the cornerstone for the prevention and management of NAFLD and should be recommended to every patient at risk or having established NAFLD. Despite the high prevalence of NAFLD, it should be recognized that the majority of patients will not develop liver-related complica...
CONCLUSION: Type 2 diabetes mellitus plays an important role in the progression of non-alcoholic fatty liver disease as an independent risk factor for severe fibrosis. PMID: 29893699 [PubMed - in process]
Nonalcoholic fatty liver disease (NAFLD) is characterized by abnormal fat accumulation in liver cells and is the most common chronic liver disease worldwide [1,2]. It is closely associated with obesity and is one of the important etiologies of hepatocellular carcinoma and liver failure . The development process of NAFLD can start from simple steatosis (NAFLD), become nonalcoholic steatohepatitis (NASH), and finally lead to cirrhosis and hepatocellular carcinoma in the absence of excessive alcohol intake [3,4].
More News: Alcoholism | Bariatric Surgery | Cancer & Oncology | Carcinoma | Eating Disorders & Weight Management | Fatty Liver Disease (FLD) | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Study | Surgery | Urology & Nephrology | Weight Loss